Biotech Values

[mcbio]

ABT’s in-house compound is also JAK-1 specific, according to today’s CC.

Well then, that's pretty bad for Galapagos IMHO as ABT would indeed be highly motivated to favor its in-house JAK over the Galapagos one, all things being equal. They also lock out potential key competition for the time being in doing the deal with Galapagos. Did ABT say how far behind their JAK is from the Galapagos one?

This actually makes me think a lot less now of Galapagos having ABT as their partner. I wonder what degree ABT having their own JAK-1 specific inhibitor played in the minds of Galapagos' management's willingness to do a deal. While this may not be a big issue in the short-term, I would think over the longer-term this is a pretty big overhang for Galapagos. Maybe I'm overreacting though.